Insider trades

Richard A. Heyman, Director of Enliven Therapeutics ELVN, has filed 0 purchases and 35 sales on the open market. Over the past 12 months that comes to a net sale of $493.8K. The latest trade was on 02/17.

Richard A. Heyman

Director
First filing
23/02/27
Trades
57 trades
Buys / sales
0 / 35
12-month net buying
−$493.8K
Last trade
02/17

Trading activity

Transactions

Trade type
Open-market sale10b5-1 plan02/1702/191,230 sh$26.18$32,201.4−5.2%
ELVN
Open-market sale10b5-1 plan01/2001/221,230 sh2 trades$26.75avg.$32,904.8−4.9%
ORIC
Open-market sale10b5-1 plan01/1601/206,700 sh2 trades$12.00avg.$80,400No record
ELVN
Open-market sale10b5-1 plan01/08–01/0901/1213,920 sh3 trades$25.02avg.$348,320.6−35.7%
ELVN
Open-market sale10b5-1 plan24/10/1824/10/221,570 sh2 trades$30.00avg.$47,100No record
Open-market sale10b5-1 plan24/10/1524/10/171,270 sh$27.67$35,140.9−1.0%
Open-market sale10b5-1 plan24/10/0424/10/082,825 sh$27.51$77,715.75−2.2%
Open-market sale10b5-1 plan24/10/0124/10/03518 sh$27.54$14,265.72−0.4%
Open-market sale10b5-1 plan24/09/1624/09/181,270 sh$22.41$28,460.7−1.0%
ELVN
Open-market sale10b5-1 plan24/08/1524/08/191,270 sh2 trades$23.25avg.$29,527−1.0%
ELVN
Open-market sale10b5-1 plan24/07/3124/08/022,351 sh2 trades$27.51avg.$64,669.52No record
Open-market sale10b5-1 plan24/07/1524/07/171,270 sh$24.80$31,496−0.9%
Open-market sale10b5-1 plan24/06/1724/06/201,270 sh$21.48$27,279.6−0.9%
Open-market sale10b5-1 plan24/05/1624/05/201,270 sh$23.74$30,149.8−0.9%
ELVN
Open-market sale10b5-1 plan24/04/11–24/04/1524/04/156,964 sh4 trades$24.11avg.$167,884.35No record
Open-market sale10b5-1 plan24/03/1924/03/211,270 sh$14.50$18,415−0.9%
Open-market sale10b5-1 plan24/02/1524/02/201,270 sh$17.42$22,123.4−0.9%
Open-market sale10b5-1 plan24/01/3024/02/011,270 sh$16.41$20,840.7−0.9%
ELVN
Open-market sale10b5-1 plan23/12/21–23/12/2223/12/26216 sh4 trades$13.00avg.$2,808No record
ELVN
Open-market sale10b5-1 plan23/12/19–23/12/2023/12/214,280 sh3 trades$13.02avg.$55,720.5No record